Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

59.82 -0.34 (-0.57%)
Streaming Delayed Price Updated: 11:11 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
A Peek at ANI Pharmaceuticals's Future Earnings
Via Benzinga
Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential
Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial... 
Via Benzinga
Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
Via Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
Via Benzinga
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
ANI Pharmaceuticals's Earnings Outlook
Via Benzinga
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.
Via Business Wire
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
Expert Ratings for ANI Pharmaceuticals
Via Benzinga
Analyst Expectations for ANI Pharmaceuticals's Future
Via Benzinga
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
From Brodsky & Smith LLC
Via GlobeNewswire
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
Via Benzinga
Topics Stocks
Exposures US Equities
Where ANI Pharmaceuticals Stands With Analysts
Via Benzinga
Looking Into ANI Pharmaceuticals's Return On Capital Employed
Via Benzinga
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals. 
Via InvestorPlace
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close... 
Via Benzinga
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Alphabet, Dover And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday. 
Via Investor's Business Daily
Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the  
Via Benzinga
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning
Via Investor Brand Network
7 A-Rated Biotech Stocks for Your August Buy List
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.